Tongli Pharmaceuticals | Income Statement
Fiscal year is April-March. All values USD Thousands.
2009
2010
2011
2012
2013
Sales/Revenue
7,442.40
8,591.90
14,655.20
15,487.10
11,106.00
Cost of Goods Sold (COGS) incl. D&A
4,281.20
4,960.40
7,942.70
10,062.20
5,831.30
Gross Income
3,161.20
3,631.50
6,712.60
5,424.90
5,274.70
SG&A Expense
1,061.00
1,729.90
672.60
2,127.40
1,127.80
EBIT
2,100.20
1,901.60
6,040.00
3,297.50
4,146.90
Unusual Expense
-
-
159.70
-
1,907.50
Non Operating Income/Expense
241.70
-
-
-
45.00
Interest Expense
182.30
73.30
58.20
24.10
37.70
Pretax Income
2,159.60
1,828.30
5,822.00
3,273.40
2,157.80
Income Tax
254.80
855.50
1,561.90
1,121.60
664.30
Consolidated Net Income
1,904.80
972.80
4,260.10
2,151.80
1,493.50
Net Income
1,904.80
972.80
4,260.10
2,151.80
1,493.50
Net Income After Extraordinaries
1,904.80
972.80
4,260.10
2,151.80
1,493.50
Net Income Available to Common
1,904.80
972.80
4,260.10
2,151.80
1,493.50
EPS (Basic)
0.19
0.10
0.37
0.17
0.11
Basic Shares Outstanding
9,968.80
10,232.20
11,541.50
12,565.10
14,097.70
EPS (Diluted)
0.19
0.10
0.37
0.17
0.11
Diluted Shares Outstanding
9,968.80
10,232.20
11,541.50
12,565.10
14,097.70
EBITDA
2,446.50
2,266.90
6,432.00
3,865.80
4,783.90
Non-Operating Interest Income
-
0.10
-
-
1.10
About Tongli Pharmaceuticals
View Profile
